iRhythm Holdings reported third-quarter 2026 revenue of $221.6 million, a 14.9% increase year-over-year, driven by volume growth in its Zio Monitor business and robust margin expansion. Gross margin improved to 74.2%, while adjusted EBITDA reached $51.2 million with a 23.1% margin. The company raised its full-year 2026 revenue guidance to between $890 million and $895 million, up from previous estimates, citing strong demand and the recent acquisition of VitalConnect. GAAP net loss widened to $29.9 million due to litigation settlements and integration costs, though adjusted net income turned positive at $27.8 million. iRhythm is a leading digital health care company that develops wearable biosensors and cloud-based analytics for ambulatory cardiac monitoring.
